Clinical Trial Goal
To find out:
- The highest dose of repotrectinib that’s safe to give
- If repotrectinib is safe and works well to treat ALCL, PCNSL or other blood cancer with ALK, ROS1, NTRK1, NTRK2 or NTRK3 mutations in children and young adults
You may be able to join this trial if you:
Your child:
- Is 25 years old or younger
- Has one of the following diseases with ALK, ROS1, NTRK1, NTRK2 or NTRK3 mutations that has relapsed or is refractory. Some examples are:
- ALCL
- PCNSL
- Other blood cancer
- You agree to have other standard tests done to see if your child can be in the clinical trial
Trial Details
Repotrectinib is a tyrosine kinase inhibitor that blocks ROS1, TRK and ALK in certain cells.
Your child will get:
Your child will get:
- Repotrectinib – A pill that your child takes by mouth. The dose your child will get depends on when they start the trial and how safe it has been
Your child may continue treatment for as long as the clinical trial doctors think it’s best for their health. Your child will have scans and/or biopsies to see how well treatment is working. The clinical trial doctors will check your child’s health for about 3 years.
The Food and Drug Administration (FDA) has approved not yet approved repotrectinib.
Contacts
BMS Study Connect Contact Center www.BMSStudyConnect.com, 855-907-3286, Clinical.Trials@bms.com
First line of the email MUST contain the NCT# and Site #.
Locations
Sponsors
lead: Turning Point Therapeutics, Inc.
